Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Validation of [-2]proPSA for the Early Detection of Prostate Cancer

Validation of [-2]proPSA for the Early Detection of Prostate Cancer

193
[-2]proPSA
Case/control
Proteomics
Prostate and Urologic Cancers Research Group
2

Primary Objective – To validate the serum %[-2]proPSA marker for the improvement of diagnosis and risk assessment of prostate cancer and reducing unnecessary biopsies.

Secondary Objectives – (1) To determine if [-2]proPSA is complementary to other PSA derivatives in a multi-marker model to improve the diagnosis and risk assessment of prostate cancer and reduce unnecessary biopsies, (2) To validate the serum %[-2]proPSA marker for the improvement of diagnosis and risk assessment of prostate cancer and reducing unnecessary biopsies in truncated PSA ranges such as 2-10 ng/mL PSA and 2-4 ng/mL PSA, (3) To determine if the [-2]proPSA marker or a combination of markers studied can aid in the identification of aggressive cancers as determined by Gleason score.
The primary outcome analysis is to calculate the sensitivity corresponding to 70% specificity, i.e. ROC(0.30), and performing hypothesis testing against a null hypothesis of sensitivity=40%, i.e. ROC(0.30)=0.40. 95% confidence intervals will be calculated for ROC(0.30) as well as for the threshold corresponding to 70% sensitivity. The secondary outcome analysis is to calculate the specificity corresponding to 95% sensitivity and its threshold. Hypothesis testing will be conducted against the null hypothesis of specificity 5%. 95% confidence intervals will be calculated for ROC-1(0.95) as well as for the threshold corresponding to 95% sensitivity. Other exploratory analyses will be performed to examine the complementary properties of %proPSA with other clinical variables (age, race, and family history, DRE) and other PSA derivatives (PSA and fPSA). Logistic regression with forward model selection will be used to combine the markers and clinical variables. The ROC curve of the predicted score will be plotted and compared to that of the model using clinical variables and existing PSA and its derivatives but without %proPSA. These analyses will be performed for the whole group, for the group with PSA 2-10 ng/mL, and for the group with PSA 2-10 ng/mL and without suspicious DRE.

No datasets are currently associated with this protocol.


2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.